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Postoperative atrial fibrillation (POAF) occurs in approximately 30% of cardiac surgery 
patients.  The complication occurs despite advances in surgical procedures.  It is associated with 
increased mortality, morbidity, and healthcare cost.  The exact pathogenesis of this complication 
is unknown, but oxidative stress and inflammation are considered to be significant factors.   
 A precisely controlled balance between reactive oxygen species (ROS) generation and 
ROS scavenging influence the oxidative environment within cells and tissues.  Increased activity 
of monoamine oxidase (MAO) activity, a ROS generating enzyme, can produce a more oxidative 
environment.  A decrease in glutathione (GSH), a ROS scavenging molecule, can also yield an 
oxidative environment.  The enzymes GSH-peroxidase (GPx) and GSH-reductase (GR) are 
responsible for maintaining the cellular redox environment within a range that is compatible with 
favorable homeostasis.  Despite the well-characterized role that these enzymes play in 
 
 
 
ii 
 
maintaining redox environment, a comprehensive evaluation of these enzymes in human 
myocardium has never been attempted. 
 Furthermore, since reports have recently documented the association between oxidative 
stress in atrial tissue and the incidence of POAF, we tested the hypothesis that these enzymes are 
associated with POAF, in a cohort of patients undergoing cardiac surgery at Vidant Medical 
Center, East Carolina Heart Institute (ECHI). 
Human right atrial appendage tissue were obtained from 244 patients undergoing elective 
coronary artery bypass graft surgery at ECHI between January, 2010, and December, 2012.  The 
generation of ROS were determined using assays on MAO, NADPH oxidase (NOX), along with 
the activity of glutathione reductase (GR) and glutathione peroxidase (GPx).  Patient outcomes, 
including POAF development, were analyzed in relation to the assays performed.  A statistical 
model was then created to measure the association for risk of POAF development.   
This was the first study to determine that MAO activity is a major source of ROS in 
human atrial tissue.  MAO activity is significantly associated with POAF.  Total glutathione 
(GSHt) activity is inversely related to POAF development.  GPx is also significantly associated 
with POAF as well, but the trend is not a linear.  GR activity is not correlated with POAF.   
MAO, GSHt and GPx are enzymes that contribute to the atrial oxidative environment and 
increased risk of POAF development.  Because this is a pilot study, further exploration is needed 
to validate our study and to determine if and where these enzymes fit in the etiology of POAF.
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1.  INTRODUCTION 
Heart disease is the leading cause of death in the United States.  Approximately 
11% of the adult population in the U.S. will develop this disease, and this rate rises to 
30.5% of patients over the age of 65.  It accounted for approximately 307,000 deaths in 
men and 290,000 deaths in women in 2010.  More specifically, it was determined that 
coronary heart disease is the main cause of approximately 1 in 6 deaths in the United 
States in 2008.1 
Yet despite the pronounced increase in heart disease in recent years, modern 
medicine has been able to keep pace and has made tremendous strides as well.  In 
particular, advancements in cardiac surgery have allowed patients with heart disease to 
live far longer, with far better quality of life, than ever before.  A recent assessment has 
documented that cardiac surgery was the most commonly performed surgery in the 
United States in 2010.  Approximately 15% of all surgical procedures that year were 
conducted on the cardiovascular system, accounting for almost 20% of all surgeries on 
patients over the age of 45.2  Cardiac catheterization was the most commonly-performed 
cardiac surgery, followed by angioplasty, coronary artery stent insertion, and coronary 
artery bypass graft (CABG) surgery.2  CABG surgery is the second-most expensive type 
of surgery for all patients over 44 years of age.3  This surgery is recommended in patients 
with severe or unstable angina, ST-segment elevation myocardial infarction, and non-ST-
segment elevation myocardial infarction, among other symptoms.4 
Although striking improvements in cardiac surgery have indeed changed the 
outcome of millions of individuals afflicted with heart disease, there are many adverse 
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consequences that have come along with those improvements.  Along with the high 
financial costs of the surgery itself, there are many postoperative complications 
associated with cardiac surgery, including respiratory failure, renal failure, and 
gastrointestinal failure.5  However, the most common complication is postoperative atrial 
fibrillation (POAF), occurring in 30% to 60% of all patients undergoing cardiac surgery 
worldwide.6  It is important to emphasize that even in non-cardiac surgical procedures, 
POAF is a common complication as well, although more variable and generally at a 
lower rate of incidence (0.3% - 29%).7 
The development of POAF can result in increased mortality, morbidity, and 
hospital cost.  Patients with POAF have an increased number of postoperative days in the 
hospital (5.8 vs. 4.4) and ICU (1.5 vs. 1.2) compared to patients who stayed in sinus 
rhythm.  There is also a higher readmission to the ICU (11% vs. 1%) and number of 
laboratory tests ordered (53.7 vs. 38.6).   Upon discharge, physicians sent fewer POAF 
patients to their home (29.4% vs. 34.6%) and more to a post-hospital care facility (19.7% 
vs. 13.1%).  In total, a patient with POAF has additional hospital charges that approached 
$12,000 in 2009.8  With almost 400,000 people having CABGs in 2010, it can be 
extrapolated that POAF adds an additional $1.4- to $2.9-billion in extra hospital charges, 
each year.2 
POAF is closely related to atrial fibrillation (AF), which is the most common 
arrhythmia found in clinical practice.9   AF is characterized as a disorder in which the 
atria do not contract in a synchronized process.  Instead it quivers, leading to hemostasis 
in the atrial compartment, ultimately putting the patient at increased risk of 
thromboembolism and stroke.  It was first described by Garrey10 as an “incoordinated 
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[sic], disorderly and extremely bizarre contractile process in which normal systole and 
diastole no longer occur”.  He continued by stating that it is a “group of fibers [that] are 
contracting independently”.10  Garrey hypothesized the pathogenesis as coming from a 
“subacute or chronic inflammatory change leading to fibrosis.”10  Cohnheim concluded a 
“metabolic poison” was the link between the lag of fibrillation after ligation of a coronary 
artery, but the actual mechanism of action was unknown.10  The etiology of AF has 
evolved since its first depiction, but some characteristics have remained.  Patients with a 
history of AF have a higher incidence of POAF.   
There are myriad factors that contribute to the development of POAF.  At a macro 
level, these factors can be either acute or chronic.  Acute factors occur during a time 
period immediately surrounding the surgery, while chronic factors are typically 
considered to be events and clinical conditions that lead up to surgery.  Age and race are 
well-documented set of non-modifiable risk factors.  Invariably, studies have repeatedly 
shown that the patient’s age is the strongest predictor of POAF.  In one study, almost 
20% of all thoracic surgical patients ≥60 years old developed POAF, while only 7% of 
the patients <60 years old developed it.11  Caucasian race is another independent 
predictor of POAF.12,13  Other chronic factors, such as structural heart disease, congestive 
heart failure, and hypertension, are known variables that contribute to atrial remodeling.  
Atrial remodeling is a diffuse term that describes a persistent change in the structure or 
function of the atria at the anatomic and/or physiological level.  These factors all play a 
part in increasing the susceptibility for a patient to develop POAF.   
Of the acute physiological factors that are associated with POAF, inflammation 
and oxidative stress are the two factors that have been studied the most, and are the 
 
 
4 
 
factors generally considered to be the most significant.  One widely-held theory is that 
the use of tubing and instrumentation of the atria, such as occurs with a cardiopulmonary 
bypass (CPB) machine or aortic cross-clamp, increases systemic inflammation and 
myocardial oxidative stress, thereby contributing to the probability of atrial injury and 
POAF.14, 15  Reperfusion that occurs after CBP causes the generation of reactive oxygen 
species (ROS) in the myocardium.  The increased oxidative stress is thought to interfere 
with the electrical conduction pathways within the atria. The “metabolic poison,” 
associated with oxidative stress and inflammation first mentioned by Cohnheim, is now 
thought to acutely contribute to the etiology of POAF.    Regardless of the specific 
mechanism, the collective effect of inflammation and oxidative stress associated with 
cardiac surgery has a pronounced impact on the patient in the immediate post-operative 
period (1-5 days).  Other acute risks are the endogenous pro- and anti-inflammatory 
molecules in circulation.  Their precise role in POAF is poorly understood.  The flux in 
the concentration of these molecules can come from anesthesia or trauma acquired from 
the surgical procedure.  There is a positive correlation between an increase in 
proinflammatory cytokines and morbidity after cardiac surgery.16 
1.1.   Inflammation and POAF 
Cardiac surgery provokes a powerful inflammatory response that can often lead to 
adverse consequences to the patient.  Inflammation is the body’s response to the 
disruption within the tissues, involving a series of controlled humoral and cellular 
reactions which elicit pro-inflammatory responses within the body.   Systemic 
inflammation is typically confirmed in the clinical setting by assessing the increase of 
circulating C-reactive protein (CRP), which indicates complement activation.    
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The intensity of atrial inflammation is correlated to the invasiveness of the 
surgery.  Heart valve surgery has the highest incidence, followed by CABG and lastly 
non-cardiac surgery.  Atrial inflammation, as determined by myeloperoxidase activity 
and neutrophil infiltration, is associated with an increase in the incidence and duration of 
AF.  Some studies found that postoperative white blood cell counts were increased in 
POAF patients.  Also CRP levels increase postoperatively until it peaks at postoperative 
day two. This time course matches the same pattern displayed by the majority of cardiac 
surgery patients developing POAF. However, although a generalized atrial tissue 
inflammation is known to be linked to POAF, there is not a single pro-inflammatory 
marker that correlates with POAF independent of other known risk factors.    In some 
studies, however, white blood cell count has been shown to be an independent predictive 
marker for POAF development.17, 18 
One of the greatest known triggers of inflammatory responses is CPB.  The use of 
the CPB machine causes two-step complement activation.  During CPB intervention, the 
‘alternative pathway’ becomes activated via Tumor necrosis factor-α (TNF-α) due to the 
blood mixing with the machine.  The second phase of activation is via the ‘classical 
pathway’ which is initiated by the anti-coagulant protamine sulfate.  POAF development 
usually overlaps with activation of the ‘classical pathway’.   Retrospective 
epidemiological studies have documented that anti-inflammatory drugs are effective in 
lowering POAF incidence.7  Some classes of drugs, such as steroids and HMG-CoA 
reductase inhibitors, can inhibit tissue inflammation associated with surgery.  This 
inhibition results in decreased CRP concentration and AF duration.  Other studies have 
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demonstrated that drugs with anti-inflammatory effects are effective at lowering the 
incidence of POAF by the inhibition of cytokine release.   
CRP is closely related to systemic inflammation and the development of 
AF.19  The peak concentration of CRP occurs on the second or third postoperative 
day.  That timing also correlates with the highest frequency of POAF.20  Overall, the 
protein is significantly increased in atrial arrhythmia patients, compared to patients who 
stay in sinus rhythm.21  Yet despite its tight correlation with POAF, CRP isn’t a good 
diagnostic molecule in predicting POAF.21  TNF-α is another cytokine strongly 
associated with POAF.  Increased levels of TNF-α are associated with severe leukocyte 
infiltration and increased fibrosis compared to patients who stay in sinus 
rhythm.  Increased levels are also found in patients with persistent AF compared to 
paroxysmal AF.22  The chance of a patient developing POAF has been significantly 
associated with increased leucocyte levels, an inflammatory marker.23  Interleukins are a 
subgroup of cytokines that are also related to POAF development. Low levels of 
interleukin-2 (IL-2) are associated with a decreased incidence of POAF.22  Interleukin-6 
(IL-6) is associated with both pro- and anti-inflammatory functions.  Among other tasks, 
it helps in the synthesis of CRP, and mediates the proliferation of TNF-α.  High levels of 
serum IL-6 are one of the best predictors associated with POAF and AF.21,22  Interleukin-
8 (IL-8) helps with the recruitment of neutrophils, and pro-thrombotic and inflammatory 
states.  Higher concentrations of IL-8 are found in patients with permanent AF, compared 
to paroxysmal AF.22 
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1.2.  Oxidative Stress and POAF  
Oxidative stress occurs when ROS generation in a cell or tissue overwhelms the 
ROS scavenging capacity leading to a disruption in homeostasis.24  When an oxygen 
radical reacts with a non-radical, it can often initiate a chain reaction, or vicious cycle 
that results in the production of more free radicals. Because of the high reactivity of 
oxygen radicals, persistent oxidative stress can lead to damage to biological systems. 
Current literature has documented a role for oxidative stress in numerous chronic human 
diseases, particularly ischemic and inflammatory diseases of the cardiovascular system.25  
Specifically, the increased production of atrial ROS are associated with atrial remodeling 
and a greater probability of AF development.26 
With regard to POAF, the use of CPB has been suggested to be a causal factor in 
ROS generation during cardiac surgery due to complement activation.  This systemic 
inflammation caused by CPB is a factor in POAF development.  There is a local 
inflammation from the actual incision that increases the incidence of POAF.  However, 
current literature has failed to show consistent evidence of an association between POAF 
and CPB.7  Since the current data are retrospective, and have a limited sample size, 
further exploration is needed to establish what specific role CPB has in myocardial or 
system ROS generation, if any.21 
1.2.1.  Sources of ROS related to POAF 
Free radicals are generated from numerous biochemical processes, including the 
reduction of molecular oxygen during aerobic respiration and the oxidation of 
catecholamines, thereby resulting in the incomplete reduction of molecular oxygen to 
 
 
8 
 
form superoxide.24  A physiologically normal function of free radicals is the capability of 
signaling and communicating.  Abnormally generated free radicals are centered on many 
diseases.25  Major sources of free radicals in cells and tissues include the mitochondria, 
xanthine oxidase (XO), NADPH oxidase (NOX), and nitric oxide synthase (NOS).27   
Within the mitochondria, molecular oxygen is reduced to water in order to 
generate energy in the form of ATP.  The energy-producing process is not perfect and 
<5% of the molecular oxygen is incompletely reduced.  This sub-species of oxygen, 
known as a superoxide radical, is thought to be the main source of ROS during ischemia 
and reperfusion, and has been suggested to be a source of ROS in the myocardium during 
the ‘warm-up’ period of reperfusion following cardioplegic arrest.27  
The membrane-bound enzyme NOX has been shown to be an important source of 
ROS in cardiomyocytes.  Atrial NOX activity has been reported to be an independent 
predictor of POAF.28  Iravanian and Dudley hypothesized perioperative inflammation 
stimulated NOX within the atria, lead to a surge in oxidative stress that subsequently 
triggered an arrhythmia.  Both NOX gene expression and protein level are up-regulated in 
patients with POAF compared to patients who stay in sinus rhythm.29  Current evidence 
shows inhibitors of NOX could provide a method to reduce or prevent the development 
of POAF.30 
Another significant generator of ROS is XO.27  During an ischemic event, the 
concentration of hypoxanthine is increased and this enzyme is used to oxidize 
hypoxanthine to xanthine.27  Gene expression has been found to be up-regulated in 
patients with POAF compared to patients who stay in sinus rhythm.29  Although this 
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enzyme system has been implicated as a source of ROS in numerous cardiovascular 
diseases, at present no connection between this enzyme and the development of an 
arrhythmia has been established in either experimental or clinical studies. 
Different isoforms of NOS are well known to be expressed in cardiac tissue.  
NOS1 and 3 are found under homeostatic conditions, while NOS2 is induced under 
pathological conditions.  During heart failure, NOS has been shown to become uncoupled 
and produce superoxide radicals.31  There are also both preclinical and clinical data 
suggesting NOS signaling has a role in the pathogenesis of AF.28  
Another source of ROS in cardiomyocytes that has been largely ignored until 
recent years is the enzyme monoamine oxidase (MAO).  This enzyme is tethered to the 
outer mitochondrial membrane, and is responsible for oxidative metabolism of 
catecholamines, in the process generating an oxidized catechol aldehyde, ammonia, and a 
hydrogen peroxide molecule.  Even in experimental models, there is a very limited 
amount of literature on MAO in regards to the heart.  One group found the isozyme 
MAO-B is significantly up-regulated in patients with persistent AF, compared to sinus 
rhythm patients.29  Investigation and characterization of this source of ROS in human 
atrial myocardium was part of the rationale for this thesis project. 
1.2.2.  Antioxidants and scavengers of ROS 
Antioxidant molecules and ROS-scavenging enzyme systems are designed to 
scavenge or reduce oxidant molecules (e.g., oxygen radicals, peroxides) before they are 
able to damage vital components in the cell.24  Antioxidant enzymes become up-regulated 
when the cell is exposed to a certain ROS threshold.27  During healthy homeostasis, 
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endogenous antioxidant systems are able to match the generated ROS.  However, a 
pathological event, such as ischemia-reperfusion, elicits a surge of ROS that develops 
over a short period of time.27  If ROS overwhelms the endogenous antioxidant system, 
tissue damage, atrial remodeling and electro-mechanical disruption could occur.32  The 
clinical use of antioxidant therapy has repeatedly established antiarrhythmic benefit in 
humans.7 
1.2.2.1.    Enzymatic ROS scavenging 
Catalase is an enzyme responsible for reducing H2O2 to H2O and O2.  This 
enzyme, when overexpressed in heart, has been previously shown to increase the lifespan 
in mice due to its positive effects on cardiac aging.33  However, the gene expression of 
this enzyme is down-regulated in patients with persistent AF, compared to patients who 
stay in sinus rhythm.29   
Superoxide dismutase (SOD) is an antioxidant that catalyzes the dismutation of 
superoxide into oxygen and hydrogen peroxide. It is the primary enzyme responsible for 
the breakdown of 
superoxide.27  The gene 
expression of this enzyme 
has also been shown to be 
down-regulated in AF 
patients compared to 
patients who stay in sinus 
rhythm.29  When animal models are given SOD during ischemia-reperfusion, the infarct 
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size is significantly decreased.  Despite showing promise in experimental models, clinical 
trials have not matched these results.27 
Glutathione is the main intracellular redox antioxidant.34  The ratio of oxidized 
(GSSG) to reduced glutathione (GSH)  in patients with AF development shows a positive 
association.35  The GSH/GSSG ratio is decreased by 50-70% in patients with ischemia, 
heart failure, and type II diabetes.  Those morbidities are all associated with 
arrhythmias.36  GSH is oxidized to GSSG by GPx, with the help of the cofactor selenium. 
The gene expression of GPx has been shown to be down-regulated in AF patients 
compared to patients who stay in sinus rhythm.29  Glutathione Reductase (GR) reduces 
GSSG back to GSH, with the cofactor flavin adenine dinucleotide (FAD)  (Figure 1).  
This antioxidant enzyme is also downregulated in AF patients compared to those in sinus 
rhythm.29 
1.2.2.2.    Non-enzymatic ROS scavenging 
Many vitamins are other antioxidants utilized by the body.  A study of rapid atrial 
pacing in a canine model reported that vitamin C decreased superoxide formation in 
heart.  The same study found that it reduced the incidence of POAF in humans.7  Vitamin 
E, a lipid-soluble antioxidant, has also been shown to reduce the development of 
ischemia/reperfusion-induced arrhythmia.  N-3 polyunsaturated fatty acids (PUFA) are 
also being studied for their ability to quell the imbalance of oxidative stress, and thus 
reduce POAF incidence.  A recent study determined a combination of PUFA and 
vitamins C and E increases the antioxidant capacity, thus decreasing POAF incidence.  It 
does this by inducing lower ROS production levels compared to the control group.37  
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1.3.  Hypothesis 
Since Cohnheim first postulated a “metabolic poison” as a cause of AF, many 
studies have been performed to investigate the relationship between oxidative stress and 
the development of POAF.10  The exact pathophysiological events that occur during 
POAF are still unknown.  This thesis seeks to address the hypothesis that MAO activity 
with other redox molecules from the right atrial appendage can be used as predictive 
biomarkers of POAF risk.   
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2.  METHODS 
2.1.  Patient enrollment and inclusion/exclusion criteria  
Approval for this study was granted by the Institutional Review Board of the 
Brody School of Medicine at East Carolina University.  A total of 244 patients 
undergoing primary, non-emergent CABG or CABG/valve surgery between January 
2009 and December 2012 were enrolled.  Patients with severely enlarged atria (>4.0 cm 
diameter), a history of arrhythmias, prior cardiac surgery, a left ventricular ejection 
fraction (LVEF) < 30% and/or history of anti-arrhythmic medication were excluded from 
this study.   
2.2.  Atrial tissue collection and processing  
Following median sternotomy, but prior to institution of cardiopulmonary bypass, 
a sample of the right atrial appendage (RAA) was resected and immediately rinsed in ice-
cold Buffer X.1  The sample was then blotted on gauze to remove excess buffer, trimmed 
of the epicardial layer, and frozen in liquid N2.  This method ensured that all samples 
obtained were predominantly myocardium and rapidly processed and frozen (< 90 
seconds from time of removal) to minimize protein and mRNA degradation.  In some 
cases viable atrial myocardium was transferred to the laboratory and used for preparation 
of permeabilized myofibers (PmFBs) and analysis of mitochondrial function.   
2.3.  Permeabilized fiber preparation  
 Portions of this technique have been described elsewhere,1 but have been adapted 
for application in human cardiac muscle and for specific measurements made in this 
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study.  After RAA tissue harvest, myocardium was removed and placed in ice-cold 
Buffer X, containing (in mM: 7.23 K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 20 
Taurine, 5.7 ATP, 14.3 PCr, 6.56 MgCl2·6H2O, 50 MES; pH 7.1).  Muscle was then cut 
into strips ~4-6 mm L x 2-3 mm wide and placed in a solution of Buffer X containing 3 
mg/ml collagenase Type I (Sigma-Aldrich, St. Louis, MO), and incubated for 30-45 
minutes at 4°C.  Fiber bundles were then carefully trimmed of vascular and connective 
tissue, separated along their longitudinal axis, and permeabilized for 30 minutes in Buffer 
X + 50 µg/ml saponin at 4°C.  We used 30 µg/ml saponin in female patients, for reasons 
described elsewhere.2  Following permeabilization, PmFBs were washed in ice-cold 
Buffer Z containing (in mM): 110 K-MES, 35 KCl, 1 EGTA, 5 K2HPO2, 3 MgCl2-6H2O, 
and 5 mg/ml BSA (pH 7.4, 295 mOsm) and remained in Buffer Z on a rotator at 4C until 
analysis (<2 hours).  We have observed that PmFBs exhibit a very strong Ca2+-
independent contraction that is temperature sensitive and can occur even at 4C,20 
therefore, 20 M Blebbistatin (Sigma-Aldrich, St. Louis, MO) was added to the wash 
buffer and the respiration medium during experiments  to prevent contraction as 
previously described. 
2.4.  Measurement of mitochondrial H2O2 emission in cardiac PmFBs  
All mitochondrial H2O2 measurements were performed at 37°C.  Hydrogen 
peroxide coming from mito-ETS as a result of palmitoyl-L-carnitine, glutamate and 
succinate oxidation was determined in PmFB’s with 100 µM ADP, 5 mM glucose and 1 
U/ml hexokinase present to keep the mitochondria in a permanent, submaximal 
phosphorylating state (i.e. most physiological).3,4 Hydrogen peroxide emission rate was 
determined in real time by continuous monitoring of Amplex Red oxidation in the 
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presence of horseradish peroxidase (1 U/ml) and SOD (25 U/ml) using a 
spectrofluorometer (Photon Technology Instruments, Birmingham, NJ,) equipped with a 
thermo-jacketed cuvette chamber. 
2.5.  MAO and NOX activity  
Myocardial samples frozen in liquid N2 were homogenized in 10X (wt./vol) TEE 
buffer containing (in mM: 10 Tris base, 1 EDTA, 1 EGTA), and 0.5% Tween-20, using a 
glass grinder (Kimble Chase, Vineland, NJ).  All enzyme activity and glutathione assays 
were performed on the same day as the protein extraction.  We have empirically 
determined that glutathione and enzyme activity must be assessed immediately in protein 
extractions to obtain accurate results, and that freezing samples or keeping them at 4°C 
overnight will cause dramatic loss of content and activity. Hydrogen peroxide generation 
from MAO and NOX was determined in real time by continuous monitoring of Amplex 
Red oxidation in presence of horseradish peroxidase (1 U/ml) and SOD (25 U/ml) using a 
spectrofluorometer (Horiba Jobin Yvon, Ann Arbor, MI) equipped with a thermo-
jacketed cuvette chamber maintained at 37°C.  MAO activity was determined by 
continuous monitoring of clorgyline-sensitive H2O2 production supported by 1 mM 
Tyramine or 2 µM Norepinephrine as previously described.5  NOX activity was 
determined by continuous monitoring of apocynin-sensitive H2O2 production supported 
by 0.5 mM NADPH.6   
2.6.  GSHt, GPx and GR activity  
 All enzyme activity and glutathione assays were performed on the same day as 
the protein extraction.  Total glutathione measurements were performed as described 
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previously 7,8 using a modified Tietze method.9  GR activity in myocardial tissue was 
measured in TEE buffer containing 1 mM GSSG and 0.5 mM NADPH, where activity 
was calculated from the linear decrease in NADPH absorbance with time.10  GPx activity 
was determined in TEE buffer containing 1 mM GSH, 100 mU/ml GR enzyme, and 0.5 
mM NADPH.  The reaction is initiated with a nominal amount of tert-Butyl-
Hydroperoxide and the activity of GPx was calculated from the linear decrease in 
NADPH absorbance with time.11 
2.7.  Determination of POAF   
Postoperatively, patients’ heart rates and rhythms were continuously monitored 
with telemetry until discharge.  POAF was defined by a sustained episode of AF lasting 
≥1 minute, or for any length of time requiring intervention for hemodynamic 
compromise. 
2.8.  Statistical Analysis  
Categorical variables were reported as frequency and percentage while continuous 
variables were reported as mean ± standard deviation, median, and interquartile range.  
Variables not previously categorized were divided into quartiles prior to statistical 
analysis.  Quartile categorization is advantageous because it limits the influence of 
outliers and allows for the assessment of trends across categories.   
Statistical significance of group comparisons for categorical variables was 
determined using Fisher’s Exact and chi-square (χ2) procedures and for continuous 
variables was determined using the Deuchler-Wilcoxon method.  Relative risk and 95% 
confidence intervals were computed using log-binomial or robust Poisson regression.   
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P-values for trends were computed using a likelihood ratio test (or score test when 
convergence was not achieved).  Assays were performed using a missing by design 
sampling strategy.  The iterative expectation-maximization (EM) algorithm was used to 
impute missing values.12-14  The relative imputation efficiency ranged from 96% to 99% 
(Variance inflation: MAO=0.38, GSHt=0.02, GPx=0.15, GR=0.54; Fraction missing 
information: MAO=0.29, GSHt=0.02, GPx= 0.14, GR=0.37). Patients with and without 
missing data did not differ by key demographic characteristics (i.e., age, sex, race; 
Hochberg adjusted p> 0.05).15 Furthermore, a complete-case analysis was performed and 
it did not substantively change the results of the study. The multivariable models included 
variables that have been previously reported to be associated with POAF, regardless of 
their statistical significance in our dataset.  These included age, sex, race, diabetes, 
hypertension, ACEI/ARB use, statin use, and CPBT.16-20  Statistical significance was 
defined as p < 0.05.  SAS Version 9.3 (Cary, NC) was used for all analyses. 
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3.  RESULTS 
3.1.  Analysis of major ROS sources in human atrial myocardium 
An assessment of 
three major ROS sources 
in atrial myocardium 
was performed from 
RAA biopsies of 12 
individual patients 
(demographic and 
clinical characteristics of these 12 patients are provided in Table 1).  Rates of H2O2 
production in the myocardial tissue homogenate was confirmed to be derived from MAO 
and NOX based on the sensitivity to their inhibitors clorgyline and apocynin, respectively 
(Figure 2A).  Hydrogen peroxide production derived from the mito-ETS was driven by 
oxidation of substrates as they were individually titrated into the respiration medium 
containing the PmFBs (Figure 2A).  Total rates of H2O2 production from these three 
sources were individually quantified and combined within each of the 12 patients (Figure 
2B).  The rate of H2O2 originating from mito-ETS was determined to be at least 10-fold 
lower than either MAO or NOX alone.  As previously reported by our group, diabetic 
patients had significantly higher rates of H2O2 from mito-ETS compared with non-
diabetic patients.3,4     
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3.2.  Patient characteristics, biochemical markers, and relationship to POAF 
A total of 80 (33%) patients 
developed POAF.  Patients with 
POAF were older and presented with 
hypertension more frequently (Table 
2).  Additionally, they experienced 
longer CPBT.  Mean MAO levels 
were significantly higher among 
patients with POAF (P<0.0001) and 
a linear trend across quartile levels was observed (Ptrend<0.0001), with the incidence of 
POAF being the highest in quartile 4 compared with quartile 1 (Figure 3).  POAF was not 
associated with GSHt, GPx, and GR (Figures 4, and 5B & C) in the univariable analysis.  
In multivariable analysis, MAO remained statistically significant after adjusting for age, 
sex, race, diabetes, hypertension, ACEI/ARB use, statin use, and CPBT (Ptrend= 0.009, 
Table 3).  A statistically significant linear trend also was observed for GSHt in 
multivariable analysis (Ptrend= 0.014). 
  
4.  DISCUSSION 
Several reports have documented the inverse association of POAF and β-blocker use, 
illustrating the underlying etiologic role of catecholamines and excessive sympathetic 
discharge.21, 22  Others have used prophylactic amiodarone,23 sotalol,24 magnesium,25 and 
statins,26 all of which were successful at reducing the incidence of POAF to varying 
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degrees; however, all patients were treated regardless of POAF status.  These studies 
illustrate the importance of investigating biological factors that may predispose patients 
to POAF.   
 The findings of this study demonstrate for the first time that MAO is a major 
source of ROS in human atrial myocardium, and its activity varies across a 50-fold range 
among patients.  It also provides evidence that atrial MAO activity serves as an 
independent predictor of POAF and lends further support to current theory that redox 
imbalance (i.e., oxidative stress) in the atrial myocardium is a significant factor in the 
etiology of POAF, particularly with respect to our myocardial GSHt-related data.  
Furthermore, the results collectively integrate a number of perioperative factors known to 
contribute to the etiology of POAF (e.g., catecholamine overload and oxidative stress). 
Investigation into the etiology of POAF has largely focused on systemic 
inflammation and oxidative stress in the post-operative period.  Redox modifications of 
ion channels and proteins have been observed to directly impact cardiomyocyte 
electrical27, 28 and mechanical29 function and has been implicated in the early stages of 
electrical remodeling which accompanies the onset of AF.30  Inflammation is 
interconnected with myocardial oxidative stress.31, 32  Circulating cytokines and 
electrophilic lipids increase strain on antioxidant mechanisms in cardiomyocytes, a 
system already burdened with buffering oxidants originating from endogenous sources 
(e.g., MAO, NOX, and mitochondria) (Figure 2).  The most important buffer of ROS in 
mammalian cells and tissues is GSH, which is converted to its oxidized form by GPx in 
the presence of hydroperoxides, and recycled back to its reduced form by NADPH-
dependent GR.  The GSH/GSSG (reduced/oxidized) redox couple is considered to be the 
 
 
27 
 
key indicator of the cellular redox environment.33  Also important to the cellular/tissue 
redox environment is the total amount of GSH (GSHt), defined as the additive amount of 
free GSH and GSSG.  A decrease in GSHt potentially increases the cell susceptibility to 
the adverse outcomes associated with oxidative stress (e.g., oxidative modifications of 
proteins, lipids, and DNA).  Our findings that GSHt and GPx are inversely correlated 
with POAF (Figures 4 & 5) suggests that a greater antioxidant capacity should lead to a 
lower incidence of POAF because of a greater buffering capacity of ROS during the post-
operative period.  Clinical trials have shown that anti-inflammatory/antioxidant therapies 
lead to a decreased incidence of POAF.34, 35  For example, pre-operative PUFAs and 
concentrated antioxidant supplementation have been observed to enhance anti-
inflammatory/antioxidant capacity in atrial myocardium at the cellular level.36  A follow-
up clinical trial with this therapy led to a substantial decrease in POAF.37  Use of n-3 
PUFAs alone as prophylactic therapy to mitigate the incidence of POAF has led to mixed 
results. For example, the omega-3 fatty acids for prevention of post-operative atrial 
fibrillation (OPERA) trial showed that very high dose (8-10 g/day) of n-3 PUFAs for 2 to 
5 days pre-operatively did not reduce the incidence of POAF.38  Nevertheless, use of n-3 
PUFAs as prophylactic therapy for arrhythmia and other cardiovascular diseases remains 
a viable therapeutic option due to the pleiotropic, beneficial effects of these fatty acids in 
the heart. 
Mitochondria, as a consequence of their intracellular volume and density, are 
considered the predominant source of intracellular ROS in myocardium.38  However, the 
total ROS that escapes (i.e. ROS emission) from the mitochondria is minimized by the 
reducing environment within the matrix of this organelle in addition to its redox enzyme 
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network.40, 41  These characteristics potentially explain our observation that H2O2 
originating from mito-ETS was markedly lower than that from either MAO or NOX 
alone (Figure 2).  ROS derived from NOX in the atrial myocardium, and downstream 
ROS (e.g., peroxynitrite and reactive aldehydes) have been shown to be significantly 
correlated with POAF.42, 43  Our findings further support the clinical importance of ROS-
generating enzymes in atrial tissue and provide novel evidence that ROS derived from 
MAO may be a key determinant of myocardial redox balance in the postoperative period.  
While MAO is an enzyme physically tethered to the outer mitochondrial 
membrane, MAO-derived ROS typically is not considered to be “mitochondrial ROS.”  
Our findings support a paradigm shift in the way this enzyme is viewed within the 
context of cellular redox balance.  The wide range in MAO activity (~50-fold) across 
patients is a significant feature of our findings (Figure 2).  Theoretically, the expression 
and activity of cardiac MAO should reflect sympathetic tone; however, there is 
considerable variation in promoter activity and transcriptional control of MAO genes in 
humans.44   This may explain the underlying variation in enzyme activity seen in our 
patient cohort.  Conceivably, high levels of catecholamines in the postoperative period 
may lead to increased concentrations inside cardiomyocytes by neuronal monoamine 
transporters in the sarcolemmal membrane.45  Thus, in patients where MAO activity is 
high (Q3 and Q4, Figure 2), MAO-derived ROS may in turn be increased, leading to 
oxidative stress and potentially triggering POAF.  In the remodeled myocardium, where 
fibrosis and altered ion channel expression are present, oxidative stress and inflammation 
only comprise a portion of the arrhythmogenic substrate.  Accordingly, therapeutic 
strategies to mitigate POAF need to account for all of these possibilities. 
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 Our study is strengthened by its prospective and systematic data collection.  
Additionally, biomarkers were obtained from myocardial tissue and reflect local cardiac 
versus serum levels.  However, several limitations should be noted.  Only the right atrial 
myocardium was collected in this study, and this may not be the best anatomic site to 
represent cardiac remodeling  and oxidative stress pathways in the heart, given the known 
importance of the left atrium as a site of arrhythmogenesis,  Moreover, studies have 
shown that as the pathology of AF progresses, a gradient of cardiac remodeling occurs 
starting in left atrium and ending in right atrium.46  The temporality and spatial 
heterogeneity of this remodeling may be missed by capturing only the right atrium.  
However, since this patient cohort did not have any prior history of arrhythmias or 
cardiac surgery, it is unlikely that any remodeling that may exist would be due to the 
presence of an atrial arrhythmia.   
Saturating concentrations of substrate (e.g., tyramine, NADPH, glutamate, etc) were 
used to measure enzyme activities in our assays.  This rarely exists in vivo.  However, the 
use of saturating substrate concentration was appropriate because the objective was to 
compare the maximal capacity for ROS generation and scavenging from myocardial 
enzymes.  Biopsies were obtained at a single point in time, therefore it was not possible 
to determine the temporality of biomarker levels.  Limited longitudinal information was 
available in our dataset.  We were unable to determine the dose, duration and frequency 
of β-blocker use prior to surgery for each patient.  Furthermore, our sample size was 
small and residual confounding may have been present.    
 In conclusion, our study suggests that MAO is a major ROS source in the human 
atrial myocardium and is an important biomarker for POAF, providing clinicians with the 
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ability to predict which patients are predisposed to this postoperative complication.  
Advanced knowledge of POAF risk will enable appropriate prophylactic treatment to be 
initiated at the time of or prior to surgery, potentially leading to reduced hospital stay and 
healthcare costs associated with this complication.  Additional investigation is needed to 
elucidate the role of MAO in arrhythmogenesis and to validate our findings in other 
populations and disease processes. 
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5.  Conclusions and Future Directions 
This thesis has explored the use of redox-associated enzymes/molecules as novel 
biomarkers for predicting risk for POAF in a cardiac surgery patient population.  
Importantly, this is the first study identifying MAO as a major source of ROS within 
human atrium.  Current literature states that redox imbalance is potentially a major causal 
factor in the etiology of POAF.  Therefore, it follows that from a mechanistic perspective 
either an increase in ROS production and/or a decrease in antioxidant capacity could lead 
to an increase in oxidative stress and consequently, the risk of POAF.  This research has 
the potential to positively impact both the patient and hospital in the very near future.   
Prophylactic treatment of patients with anti-arrhythmic medication prior to 
surgery has shown efficacy at reducing the incidence of POAF.  However, it is expensive 
and the risk of side effects strongly limits the will on the part of surgeons to administer 
this medication to every patient.  Thus, having the ability to stratify patients into either a 
‘low risk’ or a ‘high risk’ category would be very beneficial as only those patients at the 
highest risk for POAF would be treated.  Physicians using these biomarkers will have an 
additional tool in their clinical arsenal to decide if prophylactic anti-arrhythmic 
medication should be included in a particular patient.   
There are many directions for follow-up studies, because of the unique parameters 
measured and analyzed in this thesis project.  Future studies can focus on determining 
which tissue and time course develop the strongest correlation to POAF development.  
For example, the data collected in this paper came from the right atrial appendage 
following median sternotomy, but prior to the institution of cardiopulmonary bypass.  
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Further work into the possible use of whole blood and its constituents in regard to our 
biomarkers is needed, as both MAO and GSH are indeed present in blood.  If similar 
predictive trends between these markers in blood and POAF incidence are confirmed, this 
would give a less invasive technique to determine risk in a patient, and could be 
extrapolated to the general population of non-surgical patients who may also be at high 
risk for arrhythmia (atrial or ventricular).  Repeating the study in a larger patient cohort is 
needed to further confirm and validate these biomarkers as predictive of POAF.  Further 
research into the potential role of MAO, GSH and other redox enzymes in the 
pathophysiology of POAF is needed to better understand whether and to what extent 
these enzymes might be involved in arrhythmogenesis. 
A recent paper by 
Mariscalco et al derived a 
regression model to predict 
the likelihood of POAF 
using eight independent 
factors, including age and 
other co-morbidities.1 The 
independent markers do not 
include any biochemical 
markers, such as MAO.  
The addition of our independent factors could add power and increase its predictive 
nature.   
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MAO is a novel example of a biomarker able to predict POAF.  Further research 
of enzymes and molecules within cardiac tissue should be studied to determine if those 
molecules are more strongly correlated enzymes to this complication.   
 
6.  Limitations and Alternative Interpretations 
Due to the novel nature of this study, there were several limitations that need to be 
taken into account when interpreting the results.  First, patients who had a history of 
arrhythmia (AF or other), cardiac surgery, implantable defibrillator, chronic renal 
insufficiency, and the use of anti-arrhythmic drugs other than beta blockers were 
excluded from this novel study.  Prior episodes of these conditions are risk factors for 
POAF.  Future studies should have a goal of being more inclusive and have a more 
diverse cohort including these excluded diseases. 
Atrial tissue biopsies were collected from January 2009 – December 2012.  The 
samples were stored in a -70°C freezer, but some of the enzyme assays were not 
conducted until many months after biopsy.  The lag from collection to experimentation 
could result in a reduction of bioactive molecules.   The procedure dictates biopsy and 
enzyme assay on the same day.  Once a large enough data set is developed, further 
statistical correlations can be determined. 
The patient population from this study came exclusively from eastern North 
Carolina.  Consisting of the eastern 29-counties in North Carolina, this area is very 
diverse in its demographics and disease states.2, 3  Over 60% of the population is white, 
30% is black, and 3% Native American.2  Included in the disease states are a high rate of 
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cardiovascular disease and other co-morbidities, compared to the rest of North Carolina 
and the United States. 3  Eastern North Carolina has a higher rate of obesity (31.4% vs. 
27.0%), diabetes (10.6% vs. 8.6%), and hypertension (32.9% vs. 28.7%), compared to the 
rest of North Carolina.3   The heterogeneity of the population and maladies could provide 
a stronger correlation to the demographics of United States as a whole, compared to other 
studied that focus on a homogenous community.  Thus there is a greater probability of 
replicating our results in other regions of the country.   
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Appendix A: Tables 
 
TABLE 1 
 
Absent values (-) for glycated hemoglobin (HbA1c) indicate that levels were within normal 
range (4.5 – 5.9%) for that particular patient (Pt);  C, Caucasian; AA, African-American; 
HF (history of heart failure); POAF, post-operative atrial fibrillation; COPD, history of 
chronic obstructive pulmonary disease; HTN, history of hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pt. # Age Sex Race Diabetes HbA1c HF POAF Tobacco COPD Prior MI HTN
1 79 F AA Y 6.9 N N N N N Y
2 63 F C Y 10 N N Y Y Y Y
3 67 F AA Y 7.2 Y Y Y N N Y
4 62 F AA N - N N N N N Y
5 60 F C Y 9.2 N N N N N Y
6 69 F AA N - N N Y N N Y
7 47 M C N - N N N N N N
8 56 M C N - N N N N N Y
9 52 M AA N - N N Y N N Y
10 44 M C N - N N Y N Y Y
11 58 M C N - N Y N N N Y
12 52 M C Y 8.9 N Y Y N Y Y
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TABLE 2:  Patient and Operative Characteristics Stratified by Postoperative 
Rhythm Class and Univariable Relative Risk for POAF (N=244) 
Variables POAF 
n (%) 
POSR 
n (%) 
P-Value Univariable 
RR (95% CI) 
Overall 80 (33) 164 (67) --- --- 
Demographics/Comorbidities 
Age 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤56) 
     Q2 (56-64) 
     Q3 (64-71) 
     Q4 (>71) 
 
66  8.7 
67 (14) 
10 (13) 
20 (25) 
23 (29) 
27 (34) 
 
62  10 
62 (16) 
54 (33) 
39 (24) 
37 (23) 
34 (21) 
0.0019 
 
--- 
 
0.0045 
Referent 
2.2 (1.1-4.2) 
2.5 (1.3-4.7) 
2.8 (1.5-5.3) 
Ptrend=0.0008 
Sex 
     Female 
     Male 
 
14 (18) 
66 (83) 
 
41 (25) 
123 (75) 
 
0.19 
 
Referent 
1.4 (0.84-2.2) 
Race 
     White 
     Black 
 
69 (86) 
11 (14) 
 
132 (80) 
32 (20) 
 
0.27 
 
Referent 
1.3 (0.78-2.3) 
Diabetes 
     No 
     Yes 
 
50 (63) 
30 (38) 
 
84 (51) 
80 (49) 
 
0.096 
 
Referent 
0.73 (0.50-1.06) 
Hypertension 
     No 
     Yes 
 
7 (9) 
73 (91) 
 
34 (21) 
130 (79) 
 
0.019 
 
Referent 
2.1 (1.05-4.2) 
BMI* 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤26) 
     Q2 (26-30) 
     Q3 (30-33) 
     Q4 (>33) 
 
30 ± 5.7 
30 (7.4) 
23 (29) 
17 (22) 
22 (27) 
18 (23) 
 
 
30 ± 6.2 
30 (7.2) 
39 (24) 
43 (26) 
40 (25) 
42 (26) 
 
0.74 --- 
0.69 
Referent 
0.76 (0.46-1.3) 
0.96 (0.60-1.5) 
0.81 (0.49-1.3) 
Ptrend=0.60 
Smoking 
     No 
     Yes 
 
59 (74) 
21 (26) 
 
107 (65) 
57 (35) 
 
0.18 
 
Referent 
0.76 (0.50-1.2) 
COPD 
     No 
     Yes 
 
60 (75) 
20 (25) 
 
136 (83) 
28 (17) 
 
0.14 
 
Referent 
1.4 (0.92-2.02) 
Prior Stroke 
     No 
     Yes 
 
74 (93) 
6 (8) 
 
154 (94) 
10 (6) 
 
0.68 
 
Referent 
1.2 (0.60-2.2) 
Prior MI 
     No 
     Yes 
 
45 (56) 
35 (44) 
 
75 (46) 
89 (54) 
 
0.12 
 
Referent 
0.75 (0.52-1.08) 
HF 
     No 
     Yes 
 
79 (99) 
1 (1) 
 
155 (95) 
9 (5) 
 
0.089# 
 
Referent 
0.30 (0.046-1.9) 
Ejection Fraction* 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤48) 
     Q2 (48-55) 
     Q3 (55-62) 
     Q4 (>62) 
 
 
54 ± 11 
58 (10) 
17 (22) 
19 (24) 
25 (31) 
19 (24) 
 
 
53 ± 14 
54 (15) 
52 (32) 
42 (26) 
28 (17) 
42 (26) 
 
0.30 --- 
0.066 
Referent 
1.3 (0.72-2.2) 
1.9 (1.2-3.2) 
1.3 (0.72-2.2) 
Ptrend=0.15 
CAD Severity* 
     1-Vessel 
     2-Vessel 
     3-Vessel 
 
 
3 (4) 
15 (19) 
62 (77) 
 
 
11 (7) 
44 (27) 
109 (67) 
 
0.20 
 
Referent 
1.2 (0.40-3.5) 
1.7 (0.61-4.7 
Ptrend=0.079 
Left Main Disease 
     No 
     Yes 
 
65 (81) 
15 (19) 
 
135 (82) 
29 (18) 
 
0.84 
 
Referent 
1.0 (0.66-1.7) 
1.1  
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Preoperative Medications 
Beta-Blockers 
     No 
     Yes 
 
12 (15) 
68 (85) 
 
28 (17) 
136 (83) 
 
0.68 
 
Referent 
1.1 (0.67-1.9) 
ACEI/ARBS 
     No 
     Yes 
 
70 (88) 
10 (13) 
 
128 (78) 
36 (22) 
 
0.076 
 
Referent 
0.61 (0.34-1.1) 
Statins 
     No 
     Yes 
 
18 (23) 
62 (78) 
 
33 (20) 
131 (80) 
 
0.67 
 
Referent 
0.91 (0.60-1.4) 
Intraoperative Characteristics 
CPB 
     No 
     Yes 
 
3 (4) 
77 (96) 
 
10 (6) 
154 (94) 
 
0.44 
Referent 
1.4 (0.53-4.0) 
CPBT (min) 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤87) 
     Q2 (87-108) 
     Q3 (108-134) 
     Q4 (>134) 
 
120 ± 33 
115 (37) 
9 (12) 
22 (29) 
26 (34) 
20 (26) 
 
 
110 ± 37 
104 (48) 
49 (32) 
37 (24) 
35 (23) 
33 (21) 
 
0.012 
--- 
 
0.0092 
Referent 
2.4 (1.2-4.8) 
2.7 (1.4-5.4) 
2.4 (1.2-4.9) 
Biomarkers 
MAO* 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤1344) 
     Q2 (1344-2035) 
     Q3 (2035-2820) 
     Q4 (>2820) 
 
 
2843 ± 1987 
2608 (2038) 
8 (10) 
15 (19) 
19 (23) 
38 (47) 
 
 
1725 ± 1130 
1691 (1286) 
54 (33) 
44 (27) 
42 (25) 
24 (15) 
 
<0.0001 
 
--- 
 
<0.0001 
Referent 
2.0 (0.90-4.3) 
2.4 (1.1-5.1) 
4.8 (2.4-9.3) 
Ptrend<0.0001 
GSH* 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤16) 
     Q2 (16-20) 
     Q3 (20-23) 
     Q4 (>23) 
 
 
19 ± 6.0 
18 (7.6) 
24 (30) 
22 (28) 
17 (21) 
17 (22) 
 
 
20 ± 6.5 
20 (7.9) 
36 (22) 
39 (24) 
45 (27) 
44 (27) 
0.15 
 
 
--- 
 
0.36 
Referent 
0.90 (0.57-1.4) 
0.69 (0.41-1.1) 
0.70 (0.42-1.2) 
Ptrend=0.099 
GPX* 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤12) 
     Q2 (12-17) 
     Q3 (17-21) 
     Q4 (>21) 
 
 
17 ± 5.6 
17 (6.6) 
13 (16) 
25 (31) 
26 (32) 
16 (20) 
 
 
17 ± 6.9 
16 (9.4) 
48 (29) 
37 (22) 
34 (21) 
45 (27) 
 
0.42 
 
--- 
 
0.024 
Referent 
1.9 (1.1-3.3) 
2.0 (1.2-3.6) 
1.2 (0.65-2.3) 
Ptrend=0.46 
GR* 
     Mean ± SD 
     Median (IQR) 
     Q1 (≤ 3.8) 
     Q2 (4.8) 
     Q3 (5.6) 
     Q4 (>5.6) 
 
 
4.7 ± 2.5 
 
21 (26) 
21 (26) 
22 (28) 
16 (20) 
 
 
4.7 ± 2.6 
 
40 (24) 
41 (25) 
38 (23) 
45 (27) 
 
0.42 
 
--- 
0.64 
Referent 
0.98 (0.60-1.6) 
1.1 (0.66-1.7) 
0.76 (0.44-1.3) 
Ptrand=0.40 
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Test of Statistical Significance (Chi-Square for Categorical Variables, Deuchler-
Wilcoxon for Continuous Variables).  #Statistical significance computed using Fisher’s 
Exact.  Ptrend computed using likelihood ratio trend test.  *Missing values imputed using 
EM algorithm (n=10 simulations).  ACEI=angiotensin converting enzyme inhibitor; 
ARB=angiotensin receptor blocker; BMI=body mass index; CAD=coronary artery 
disease; CI=confidence interval; COPD=chronic obstructive pulmonary disease; 
CPBT=cardiopulmonary bypass time; GPX=glutathione peroxidase; GR=glutathione 
reductase; GSH=glutathione; HF=heart failure; LOS=length of stay; MAO=monoamine 
oxidase; MI=myocardial infarction; POAF=postoperative atrial fibrillation; 
POSR=postoperative sinus rhythm; Q1=first quartile; Q2=second quartile; Q3=third 
quartile; Q4=fourth quartile; Ref=referent; RR=relative risk; SD=standard deviation. 
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TABLE 3:  Multivariate Analysis of Independent Risk Factors Predictive of POAF‡  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‡Models adjusted for age, sex, race, diabetes, angiotensin converting enzyme inhibitor and 
angiotensin receptor blocker use, statin use, and hypertension.  *Missing values imputed 
using EM algorithm (n=10 simulations).   Ptrend computed using score trend test.  
CI=confidence interval; GPX=glutathione peroxidase; GSHt=total glutathione; 
MAO=monoamine oxidase; Q1=first quartile; Q2=second quartile; Q3=third quartile; 
Q4=fourth quartile; ARR=adjusted relative risk. 
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Appendix B: Figure Reproduction: 
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Figure 2. Comparative analysis of major ROS sources in human atrial myocardium.  
Shown in A are representative H2O2 production traces from NOX (blue), MAO (red) and 
mito-ETS (black dash) in RAA tissue obtained from one individual patient.  PmFBs were 
used for determining H2O2 from mito-ETS, while homogenate was used for NOX and 
MAO.  Substrates were added to cuvette where indicated. Apocynin and Clorgyline are 
administered where indicated to confirm the source of H2O2 production to be NOX and 
MAO, respectively.  In B are the quantified rates from each of these three sources in 
RAA tissue obtained from 12 individual patients. 
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Figure 3. MAO activity in atrial myocardium and incidence of POAF.  All rates of 
MAO activity from entire cohort of patients recruited for this study are shown (1 circle = 
1 patient).  Quartiles of pooled data were generated, and univariable analysis performed 
with POAF as the outcome variable using Poisson regression.  Each quartile is delineated 
with color shading to illustrate the risk of POAF within that particular quartile (Green = 
<15%, Yellow = 15-30%, Orange = 30-40%, Red = >40%).  Within each quartile, POAF 
incidence = number of patients in that particular quartile experiencing POAF.  RR = 
Relative Risk, with 95% confidence interval (CI).   
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Figure 4. Total GSH (GSHt) in atrial myocardium and incidence of POAF.  Data 
shown in this figure is GSHt for the entire cohort of patients recruited for this study.  
Quartiles of pooled data were generated, and univariable analysis performed with POAF 
as the outcome variable using Poisson regression.   Each quartile is delineated with color 
shading to illustrate the risk of POAF within that particular quartile (Red = >40%, 
Yellow = 15-30%, Orange = 30-40%).  Within each quartile, POAF incidence = number 
of patients in that particular quartile experiencing POAF.  RR = Relative Risk, with 95% 
confidence interval (CI).   
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Figure 5.  GPx-GR activity in atrial myocardium and incidence of POAF.  Shown in 
panel A is a simplified schematic of the redox cycle involving GSH and related enzymes 
GPx and GR (HOO-Lipid = Lipid peroxide).  Data shown in panel B are GPx activity and 
C GR activity for the entire cohort of patients recruited for this study.  Quartiles of 
pooled data were generated, and univariable analysis performed with POAF as the 
outcome variable using Poisson regression.  Each quartile is delineated with color 
shading to illustrate the risk of POAF within that particular quartile (Red = >40%, 
Yellow = 15-30%, Orange = 30-40%).  Within each quartile, POAF incidence = number 
of patients in that particular quartile experiencing POAF.  RR = Relative Risk, with 95% 
confidence interval (CI).   
  
 
 
54 
 
 
  
 
 
55 
 
Appendix C: East Carolina University and Medical Center Institutional Review Board 
Letter of Approval  
 
 
 
56 
 
  
 
 
57 
 
  
 
 
58 
 
  
 
 
59 
 
  
 
 
60 
 
  
 
 
61 
 
 
 
 
62 
 
EAST  CAROLINA  UNIVERSITY 
University & Medical Center Institutional Review Board Office  
1 L-09 Brody Medical Sciences Building· Mail Stop  682 
600 Moye Boulevard · Greenville, NC  27834 
Office  252-744-2914  · Fax  252-744-2284  ·  www.ecu.edu/irb 
  
Notification of Continuing Review Approval 
From: Biomedical IRB 
To: Ethan Anderson 
CC: 
  
Date: 10 /27/2011  
Re: CR00000051   
UMCIRB 09-0669   
[ IMPORTED] Linking Redox Chemistry and Mitochondria in Atrium to Post-Operative Arrhythmia 
I am pleased to inform you that at the convened meeting on  10 /26/2011 12:00 PM of  Biomedical IRB , this 
research study underwent a continuing review and the committee voted to approve the study. Approval of 
the study and the consent form(s) is for the period of  10/26/2011 to  10/25/2012 . 
The  Biomedical IRB deemed this study  Greater than Minimal Risk . 
Changes to this approved research may not be initiated without UMCIRB review except when necessary to 
eliminate an apparent immediate hazard to the participant. All unanticipated problems involving risks to 
participants and others must be promptly reported to the UMCIRB. The investigator must submit a continuing 
review/closure application to the UMCIRB prior to the date of study expiration. The investigator must adhere 
to all reporting requirements for this study. 
The approval includes the following items: 
  
Name Description Modified Version
Informed Consent - POAF study v4 
10-11-2011 .doc 
Consent Forms 
10/11/2011 
9:24 AM 
0.01 
Revised protocol for 09-0669 
Sept2011.doc 
Study Protocol or Grant 
Application 
10/11/2011 
 AM 9:19 
0.01 
The following UMCIRB members were recused for reasons of potential for Conflict of Interest on this research 
study: 
  None 
  None 
The following UMCIRB members with a potential Conflict of Interest did not attend this IRB meeting: 
 
 
 
63 
 
EAST  CAROLINA  UNIVERSITY 
University & Medical Center Institutional Review Board Office  
4N-70 Brody Medical Sciences Building· Mail Stop 682 
600 Moye Boulevard · Greenville, NC 27834 
Office 252-744-2914 · Fax 252-744-2284 · www.ecu.edu/irb 
Notification of Continuing Review Approval 
Biomedical IRB 
Ethan Anderson 
10/10/2012  
CR00000583  
UMCIRB 09-0669  
[IMPORTED] Linking Redox Chemistry and Mitochondria in Atrium to Post-
Operative Arrhythmia 
I am pleased to inform you that at the convened meeting of the Biomedical IRB on 10/10/2012, 
this research study underwent a continuing review and the committee voted to approve the 
study.  Approval of the study and the consent form(s) is for the period of 10/10/2012 to 
10/9/2013. 
The Biomedical IRB deemed this study Greater than Minimal Risk. 
Changes to this approved research may not be initiated without UMCIRB review except when 
necessary to eliminate an apparent immediate hazard to the participant. All unanticipated 
problems involving risks to participants and others must be promptly reported to the UMCIRB. 
The investigator must submit a continuing review/closure application to the UMCIRB prior to 
the date of study expiration. The investigator must adhere 
to all reporting requirements for this study. 
The approval includes the following items: 
Informed Consent - POAF study v4 10-
11Revised protocol for 09-0669 
Sept2011.doc Description Modified
 Version 
Consent Forms 
10/11/2011 9:24
AM 0.01 
Study Protocol or GrantApplication10/11/2011 9:19AM0.01 
 
 
 
1 
 
Name 
2011 .doc 
study:  None 
Anderson 
  
  
The following UMCIRB members were recused for reasons of potential for Conflict of Interest 
on this research The following UMCIRB members with a potential Conflict of Interest did not 
attend this IRB meeting: E. 
IRB00000705 East Carolina U IRB #1 (Biomedical) IORG0000418 
IRB00003781 East Carolina U IRB #2 (Behavioral/SS) IORG0000418 IRB00004973 
 
   
 
 
 
2 
 
  
From: 
To: 
CC: 
  
Date: 
Re: 
tab in the study workspace). 
  
  
Document 
study: 
  None 
E. Anderson 
EAST  CAROLINA  UNIVERSITY 
University & Medical Center Institutional Review Board Office  
4N-70 Brody Medical Sciences Building· Mail Stop 682 
600 Moye Boulevard · Greenville, NC 27834 
 Office 252-744-2914  · Fax 252-744-2284  · www.ecu.edu/irb 
Notification of Continuing Review Approval 
Biomedical IRB 
Ethan Anderson 
9/26/2013  
CR00001312  
UMCIRB 09-0669  
[IMPORTED] Linking Redox Chemistry and Mitochondria in Atrium to Post-
Operative Arrhythmia 
I am pleased to inform you that at the convened meeting on 9/25/2013 of the Biomedical 
IRB, this research study underwent a continuing review and the committee voted to 
approve the study.  Approval of the study and the consent form(s) is for the period of 
9/25/2013  to 9/24/2014. 
The Biomedical IRB deemed this study Greater than Minimal Risk. 
Changes to this approved research may not be initiated without UMCIRB review except 
when necessary to eliminate an apparent immediate hazard to the participant. All 
unanticipated problems involving risks to participants and others must be promptly reported 
to the UMCIRB. The investigator must submit a continuing review/closure application to the 
UMCIRB prior to the date of study expiration. The investigator must adhere to all reporting 
requirements for this study. 
Approved consent documents with the IRB approval date stamped on the document should 
be used to consent participants (consent documents with the IRB approval date stamp are 
found under the Documents The approval includes the following items: 
Description 
 Informed Consent - POAF study v4 10-11-2011.doc(0.01) Consent Forms 
 Revised protocol for 09-0669 Sept2011.doc(0.01) Study Protocol or Grant Application 
 
 
 
3 
 
The following UMCIRB members were recused for reasons of potential for Conflict of Interest on 
this research 
The following UMCIRB members with a potential Conflict of Interest did not attend this IRB 
meeting: 
http://epirate.ecu.edu/app/Doc/0/412EJJ69RC3KR4UB59GTNI5TAD/fromString.html 1/2 
 
 
